Siglec-F Antibody (238047) [Unconjugated]

Recombinant Mouse Siglec‑F Fc Chimera (Catalog # 1706-SF), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Mouse Siglec‑F Fc Chimera (5 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Siglec-F Monoclonal Antibody (Catalog # MAB17061). The ND50 is typically 0.1‑0.5 µg/mL.

• Reactivity: Mu
• Applications: B/N
• Clone: 238047
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Unconjugated
• Concentration: LYOPH

Siglec-F Antibody (238047) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse Siglec-F
  Asp18-Thr437
  Accession # Q920G3
• Specificity: Detects mouse Siglec-F in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse Siglec-2 or -3, or recombinant human Siglec-5, -7, -9, -10, or -11 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Gene: Siglecf
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 0.1-0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Siglec-F Antibody (238047) [Unconjugated]

• SAF2
• sialic acid binding Ig like lectin 8
• SIGLEC-8
• SIGLEC8L
• SiglecF
• Siglec-F

Background

Siglecs (1) (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins (2) belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding (3), followed by varying numbers of Ig-like C2-type domains (1, 4). Eleven human Siglecs have been cloned and characterized (1, 4). They are sialoadhesin/CD169/Siglec-1, CD22/Siglec-2, CD33/Siglec-3, Myelin-Associated Glycoprotein (MAG/Siglec-4a) and Siglec 5 to 11 (4‑6). To date, no Siglec has been shown to recognized any cell surface ligand other than sialic acids, suggesting that interactions with glycans containing this carbohydrate are important in mediating the biological functions of Siglecs. Siglec 5 to 11 share a high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. They are collectively referred to as CD33-related Siglecs. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system (4, 5). This fact, together with the presence of two conserved immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tails, suggests that CD33-related Siglecs are involved in the regulation of cellular activation within the immune system.

Mouse Siglec-F cDNA encodes a 569 amino acid polypeptide with a hydrophobic signal peptide, an N-terminal Ig-like V-type domain, three Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail (7). The expression of Siglec-F is restricted to the cells of myelomonocytic lineage. Mouse Siglec-F is likely an ortholog of human Siglec-5. Unlike many human CD33-related Siglecs, which show similar binding to both alpha 2,3- and alpha 2,6-linked sialic acids, mouse Siglec-F preferentially recognize alpha 2,3-linked sialic acid.

1. Crocker, P.R. et al. (1998) Glycobiology 8:v.
2. Powell, L.D. et al. (1995) J. Biol. Chem. 270:14243.
3. May, A.R. et al. (1998) Mol. Cell 1998. 1:719.
4. Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
5. Crocker, P.R. et al. (2001) Immunology 103:137.
6. Angata, T. et al. (2002) J. Biol Chem. 277:24466.
7. Angata, T. et al. (2001) J. Biol Chem. 276:45128.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Siglec-F Antibody (MAB17061)(9)

Publications using MAB17061

• Willems, M;Hamaidia, M;Fontaine, A;Grégoire, M;Halkin, L;Vilanova Mañá, L;Terres, R;Jamakhani, M;Deshayes, S;Brostaux, Y;Heinen, V;Louis, R;Duysinx, B;Jean, D;Wasielewski, E;Scherpereel, A;Blanquart, C;Willems, L; The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity EBioMedicine 2024-10-28 [PMID: 39471751] (Neutralization, Mouse)
• C Li, LA Ward, A Nguyen, E Lam, D Dasoveanu, M Ahmed, K Haniuda, MB Buechler, HH He, B Ludewig, KM McNagny, JL Gommerman Neonatal LTbetaR signaling is required for the accumulation of eosinophils in the inflamed adult mesenteric lymph node Mucosal Immunology, 2022-02-18;0(0):. 2022-02-18 [PMID: 35181738] (In Vivo, Mouse)
• Alisha Chetty, Matthew G. Darby, Pia M. Vornewald, Mara Martín-Alonso, Anna Filz, Manuel Ritter et al. Il4ra-independent vaginal eosinophil accumulation following helminth infection exacerbates epithelial ulcerative pathology of HSV-2 infection Cell Host & Microbe 2021-04-14 [PMID: 33857419]
• Jia-Nan Cheng, Wen Luo, Chengdu Sun, Zheng Jin, Xianghua Zeng, Peter B. Alexander et al. Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy Science Advances 2021-01-29 [PMID: 33514544] (In vivo assay, Mouse)
• Ophir Shani, Tatiana Vorobyov, Lea Monteran, Dor Lavie, Noam Cohen, Yael Raz et al. Fibroblast-derived IL-33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type-2 immunity Cancer Research 2020-12-01 [PMID: 33023944]
• S Jia, W Li, P Liu, LX Xu A role of eosinophils in mediating the anti-tumour effect of cryo-thermal treatment Sci Rep, 2019-09-13;9(1):13214. 2019-09-13 [PMID: 31519961] (In Vivo, Mouse)
• Z Noor, K Watanabe, MM Abhyankar, SL Burgess, EL Buonomo, CA Cowardin, WA Petri Role of Eosinophils and Tumor Necrosis Factor Alpha in Interleukin-25-Mediated Protection from Amebic Colitis MBio, 2017-02-28;8(1):. 2017-02-28 [PMID: 28246365] (Neutralization, Mouse)
• Besnard A, Guabiraba R, Niedbala W, Palomo J, Reverchon F, Shaw T, Couper K, Ryffel B, Liew F IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog, 2015-02-06;11(2):e1004607. 2015-02-06 [PMID: 25659095] (Bioassay, Mouse)
• Chu V, Beller A, Rausch S, Strandmark J, Zanker M, Arbach O, Kruglov A, Berek C Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity, 2014-04-17;40(4):582-93. 2014-04-17 [PMID: 24745334] (Neutralization, Mouse)

Bioinformatics

• Gene Symbol: Siglecf
• Uniprot:
  • Q920G3()